Ultragenyx Pharmaceu (RARE): Congress and insider trades
Who in Congress and inside the company traded RARE, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- Ultragenyx Pharmaceu (RARE) is a listed stock on NASDAQ.
- 3 members of Congress filed 4 buys and 2 sells of RARE, the latest published 2026-04-08 (8 April 2026).
- Insiders filed 0 open market buys worth $0 and 6 sells worth $425K, the latest filed 2026-09-08 (8 September 2026).
- Across 4 scored buys, Congress averaged +3.9% against the S&P 500 (SPY) over the 90 days after disclosure, with 50% of them ahead of the index. That result is too few trades to draw a conclusion.
- Data as of 2026-09-29 (29 September 2026).
Congress trades in RARE
as of 2026-04-08| Filed | Member | Type | Size | Days to file | 90 day vs S&P |
|---|---|---|---|---|---|
| 8 Apr 2026 | Gil Cisneros (D-CA) | buy | 1K–15K | 35 | +35.1% |
| 10 Mar 2026 | Gil Cisneros (D-CA) | buy | 1K–15K | 19 | -6.7% |
| 9 Feb 2022 | Ro Khanna (D-CA) | sell | 1K–15K | 18 | n/a |
| 9 Feb 2022 | Ro Khanna (D-CA) | sell | 1K–15K | 28 | n/a |
| 10 Jan 2022 | Ro Khanna (D-CA) | buy | 1K–15K | 24 | +15.0% |
| 9 Sep 2021 | Kurt Schrader (D-OR) | buy | 1K–15K | 9 | -27.8% |
Nothing matches that search.
Insider trades in RARE
as of 2026-09-08| Filed | Insider | Type | Shares | Price | Value | 90 day vs S&P |
|---|---|---|---|---|---|---|
| 8 Sep 2026 | Huizenga Theodore Alan | sell | 161 | $13.99 | $2.3K | n/a |
| 15 Jun 2026 | Parschauer Karah Herdman | sell | 1,899 | $24.62 | $46.8K | n/a |
| 15 Jun 2026 | Sanders Corazon (Corsee) D. | sell | 2,000 | $25.05 | $50.1K | n/a |
| 1 Jun 2026 | Horn Howard | sell | 4,653 | $23.77 | $111K | n/a |
| 4 May 2026 | Horn Howard | sell | 4,683 | $24.90 | $117K | n/a |
| 2 Apr 2026 | Horn Howard | sell | 4,683 | $20.97 | $98.2K | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought RARE?
4 Congress buys by 3 members and 0 insider buys are on file. The tables on this page list every one.
Did buying RARE after a disclosure beat the market?
Across 4 scored buys, Congress averaged +3.9% against the S&P 500 (SPY) over the 90 days after disclosure, with 50% of them ahead of the index. That result is too few trades to draw a conclusion. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.